The following is a summary of the Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Chimerix reported a net loss of $22.9 million for Q3 2024, an improvement from a net loss of $24 million in Q3 2023.

• R&D expenses increased to $19.6 million, primarily due to spending in the ACTION study.

• G&A expenses decreased to $5.2 million, down from $9.3 million due to a one-time non-cash expense related to historical grants recognized in 2023.

• Chimerix ended the quarter with $152 million in cash and cash equivalents, maintaining a cash runway into Q4 2026.

Business Progress:

• Phase 3 ACTION study of Dordaviprone nearing complete enrollment; interim results expected within a year.

• Positive interim safety review from the independent Data Monitoring Committee for ACTION study.

• Plans to file an NDA for provisional approval in Australia by year-end, with a potential U.S. launch following.

• Preparations underway for potential commercialization of Dordaviprone, anticipating significant market uptake.

• Phase 1 dose escalation studies for ONC206 nearing completion with next steps to be announced soon.

Opportunities:

• Anticipated rapid uptake and significant market opportunity for Dordaviprone, with a potential global market over $750 million.

Risks:

• The global Phase 3 ACTION study's success is pivotal for future regulatory approvals and Dordaviprone's market potential.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.